Logo
Login
$TLSI
$3.80 +$0.18 (4.97%) Close

Company Executives

$TLSI Management Team

Ms. Mary Szela

President

Chief Executive Officer

Director

Age 62
Compensation $4.137M USD
Sex Female

Mr. David Patience

Chief Financial Officer

Age 39
Compensation -
Sex Male

Mr. Dan Giordano

Vice President - Finance

Age -
Compensation -
Sex Male

Ms. Jennifer Stevens

Chief Regulatory Officer

Age 64
Compensation -
Sex Female

Mr. Jeremy Feffer

Investor Relations

Age -
Compensation -
Sex Male

Mr. Mats Wahlstrom

Independent Non-Executive Chairman of the Board

Age 70
Compensation $243.8K USD
Sex Male

Ms. Jodi Devlin

Chief of Clinical Operations

Age 63
Compensation $1.384M USD
Sex Female

Dr. Richard Marshak

Chief Commercial Officer

Age 66
Compensation -
Sex Male

Dr. Bryan Cox

Chief of Research

Age 63
Compensation -
Sex Male

Board of Directors

From the proxy statement filed Mar 31, 2026
Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
3.9 years
from year joined
CEO also chairs the board
No
Mats Wahlström
Director Age On board Independent Committees Other public boards 2025 pay Source
Mary Szela
CEO
 62 2018
8 years
 Not stated None stated Kura Oncology, AbSci, Averin Capital Paid as CEO
Gary Gordon
73 2025
1 year
 Independent None stated None stated $220,085
Kerry Hicks
66 2021
5 years
 Independent None stated None stated $116,249
William Valle
65 2025
1 year
 Independent None stated None stated $240,710
Michael P. Stansky
67 2026
0 years
 Independent None stated None stated Not stated
Mats Wahlström
Board chair
 71 2017
9 years
 Independent None stated Coherus Oncology, Inc. $138,749
David J. Matlin
64 2023
3 years
 Independent None stated Clene, Inc. $128,748

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

6 disclosed in the proxy filed Mar 31, 2026
Dr. Desai
a member of the Board at the time of the Offer
Amount not stated
2024

Exchanged 246,667 Exchange Warrants for 74,000 shares of Common Stock in the warrant exchange offer.

Open in proxy
Frankenius Equity AB
a holder of greater than 5% of TriSalus capital stock
Amount not stated

Purchased 62,972 shares of Common Stock in the December 2024 private placement.

Open in proxy
Mr. Dewey
a holder of greater than 5% of TriSalus capital stock as of the purchase date
Amount not stated

Purchased 50,377 shares of Common Stock in the December 2024 private placement.

Open in proxy
Mr. Wahlström
the Chairman of our Board
Amount not stated

Purchased 25,188 shares of Common Stock in the December 2024 private placement.

Open in proxy
Mr. Pallotta
a holder of greater than 5% of TriSalus capital stock as of the purchase date
Amount not stated

Purchased 200,000 shares of Common Stock in the April 2025 private placement.

Open in proxy
Mr. Dewey
a holder of greater than 5% of TriSalus capital stock as of the purchase date
Amount not stated

Purchased 62,500 shares of Common Stock in the April 2025 private placement.

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans